Journal article icon

Journal article

Safety and efficacy of ticagrelor versus clopidogrel for carotid artery stenting: propensity score matched analysis

Abstract:
Background: Dual antiplatelet therapy (DAPT) is recommended around carotid artery stenting (CAS) to reduce periprocedural stroke risk. Clopidogrel is widely used, but response variability related to pharmacokinetics and CYP2C19 polymorphisms may limit its effectiveness. Ticagrelor is a more potent, direct acting P2Y12 inhibitor, but its comparative effectiveness in CAS remains uncertain. Methods: We conducted a retrospective cohort study in the TriNetX database, identifying adults with carotid artery stenosis who underwent CAS between January 2016 and August 2025 and received either ticagrelor or clopidogrel. Primary outcomes at 180 days included ischemic stroke, major hemorrhage, intracranial hemorrhage, and all cause mortality. Secondary outcomes included inpatient readmission and emergency department (ED) visits. Propensity score matching (1:1), Kaplan–Meier survival, and Cox proportional hazards analysis were used. Results: Among 6996 patients, 378 received ticagrelor and 6618 received clopidogrel; aspirin co-use was similar (89.7% vs 91.7%). After matching, 377 patients remained in each cohort. Ischemic stroke (2.7% vs 4.2%; HR 0.56, 95% CI 0.25 to 1.27; P=0.159) and major hemorrhage (2.9% vs 4.8%; HR 0.61, 95% CI 0.29 to 1.30; P=0.197) were numerically lower with ticagrelor. Rates of intracranial hemorrhage were similar (2.7% vs 2.7%; HR 0.61, 95% CI 0.14 to 2.53; P=0.488). Mortality was numerically higher with ticagrelor (3.4% vs 2.7%; HR 1.64, 95% CI 0.68 to 3.97; P=0.263). ED visits were similar (14.3% vs 14.6%; HR 0.97, 95% CI 0.67 to 1.42; P=0.895). Inpatient readmission was numerically lower with ticagrelor (15.9% vs 19.1%; HR 0.81, 95% CI 0.57 to 1.14; P=0.223). Conclusion: Ticagrelor and clopidogrel showed comparable safety and effectiveness following CAS. Future prospective genotype informed trials are warranted to confirm these findings.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1136/jnis-2025-024658

Authors

More by this author
Role:
Author
ORCID:
0009-0009-2075-6562
More by this author
Role:
Author
ORCID:
0000-0003-2455-748X
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Role:
Author
ORCID:
0000-0002-5208-8425
More by this author
Role:
Author
ORCID:
0000-0001-8325-2382



Publisher:
BMJ Publishing Group
Journal:
Journal of NeuroInterventional Surgery More from this journal
Pages:
jnis-2025-024658
Article number:
jnis-2025-024658
Publication date:
2026-01-13
Acceptance date:
2025-12-30
DOI:
EISSN:
1759-8486
ISSN:
1759-8478


Language:
English
Keywords:
Pubs id:
2358810
UUID:
uuid_1e1e4b6c-c272-450d-bd89-ef37231430e8
Local pid:
pubs:2358810
Source identifiers:
3680995
Deposit date:
2026-01-21
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP